Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Soh, Sheila Xinxuan ^a   Lim, Joshua Yew Suang ^b   Huang, John W J ^a   Jiang, Nan ^b   Yeoh, Allen Eng Juh ^b,c,d   Ong, S Tiong ^a,e,f,g  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BIM PROTEIN; CASPASE 3; DEXAMETHASONE; GLUCOCORTICOID; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VINCRISTINE; ZINC FINGER NUCLEASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; GLUCOCORTICOID RECEPTOR; MEMBRANE PROTEIN; ONCOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BIM GENE; CANCER CELL LINE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; REGULATORY MECHANISM; DEFICIENCY; GENETICS; INFANT; METABOLISM, INBORN ERRORS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; GENE DELETION; HUMANS; INFANT; MALE; MEMBRANE PROTEINS; METABOLISM, INBORN ERRORS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; RECEPTORS, GLUCOCORTICOID; RETROSPECTIVE STUDIES;

EID: 84905497355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103435     Document Type: Article

References (50)

1. Mullighan CG (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012: 389-396.
2. Pui CH, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166-178. (Pubitemid 43076714)
3. Locatelli F, Schrappe M, Bernardo ME, Rutella S (2012) How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120: 2807-2816.
4. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143. (Pubitemid 41039160)
5. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, et al. (2009) IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 27: 5202-5207.
6. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, et al. (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22: 153-166.
7. McLeod HL (2013) Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339: 1563-1566.
8. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, et al. (2010) Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 28: 4029-4037.
9. Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, et al. (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121: 5145-5153.
10. Xu H, Cheng C, Devidas M, Pei D, Fan Y, et al. (2012) ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 30: 751-757.
11. Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, et al. (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27: 5972-5978.
12. Rocha JC, Cheng C, Liu W, Kishi S, Das S, et al. (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105: 4752-4758. (Pubitemid 40807300)
13. Perez-Andreu V, Roberts KG, Harvey RC, Yang W, Cheng C, et al. (2013) Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 45: 1494-1498.
14. Yang JJ, Cheng C, Devidas M, Cao X, Campana D, et al. (2012) Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120: 4197-4204.
15. Yang JJ, Cheng C, Yang W, Pei D, Cao X, et al. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301: 393-403.
16. Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31: 397-405.
17. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18: 521-528.
18. Morel F, Ka C, Le Bris MJ, Herry A, Morice P, et al. (2003) Deletion of the 59ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis. Leuk Lymphoma 44: 1333-1338. (Pubitemid 36764287)
19. Jabbour E, Cortes JE, Kantarjian HM (2009) Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 84: 161-169.
20. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, et al. (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 65: 9436-9444. (Pubitemid 41508012)
21. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738. (Pubitemid 129515880)
22. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4: 1681-1689; discussion 1690.
23. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, et al. (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4: e294.
24. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24: 6172-6183. (Pubitemid 38891120)
25. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103: 14907-14912. (Pubitemid 44527827)
26. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, et al. (2005) BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106: 4131-4138. (Pubitemid 41775918)
27. Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, et al. (2008) The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 22: 370-377. (Pubitemid 351250542)
28. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 278: 23861-23867. (Pubitemid 36830212)
29. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, et al. (2006) Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 107: 2061-2069. (Pubitemid 43292367)
30. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, et al. (2010) Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 116: 3013-3022.
31. Abrams MT, Robertson NM, Yoon K, Wickstrom E (2004) Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 279: 55809-55817. (Pubitemid 40066588)
32. Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, et al. (2011) BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 39: 321-329.
33. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, et al. (1998) Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92: 259-266. (Pubitemid 28303201)
34. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, et al. (2003) Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21: 3262-3268. (Pubitemid 46606259)
35. Lauten M, Moricke A, Beier R, Zimmermann M, Stanulla M, et al. (2012) Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 97: 1048-1056.
36. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, et al. (1999) Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94: 1209-1217. (Pubitemid 29380401)
37. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, et al. (1998) Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92: 2730-2741. (Pubitemid 28469086)
38. Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, et al. (2012) Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 30: 2384-2392.
39. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, et al. (1965) Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 18: 522-529.
40. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH (1985) Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65: 21-31. (Pubitemid 15191033)
41. Miyagi T, Ohyashiki J, Yamato K, Koeffler HP, Miyoshi I (1993) Phenotypic and molecular analysis of Ph1-chromosome-positive acute lymphoblastic leukemia cell lines. Int J Cancer 53: 457-462. (Pubitemid 23047895)
42. Juan WC, Roca X, Ong ST (2014) Identification of cis-Acting Elements and Splicing Factors Involved in the Regulation of BIM Pre-mRNA Splicing. PLoS One 9: e95210.
43. DeVita VT Jr, Lawrence TS, Rosenberg SA (2008) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins. pp 427, 451, 490.
44. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, et al. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114.
45. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10: 331-342. (Pubitemid 44512194)
46. Pieters R, Kaspers GJ, van Wering ER, Huismans DR, Loonen AH, et al. (1993) Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7: 392-397. (Pubitemid 23093097)
47. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ (1995) Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19: 407-416.
48. Augis V, Airiau K, Josselin M, Turcq B, Mahon FX, et al. (2013) A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib. PLoS One 8: e78582.
49. Gagne V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, et al. (2013) Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res 19(18): 5240-5249.
50. Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, et al. (2013) Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway in childhood acute lymphoblastic leukemia outcome. Haematologica. doi: 10.3324/haematol.2013.085340.